熱門資訊> 正文
武田因阿米蒂扎的“延迟付费”计划被判有罪
2026-05-19 04:57
- A federal jury in Boston on Monday found that Takeda Pharmaceutical (TAK) is guilty of conspiring to delay a generic version of its constipation drug Amitza (lubiprostone).
- The jurors found that Takeda came to a reverse payment arrangement, also known as a "pay-for-delay" scheme, with generic drugmaker Par Pharmaceutical that led to health plans and pharmacies—including CVS (CVS)—to overpay hundreds of millions of dollars, Reuters reported.
- The tactic involves a brand manufacturer paying a generic company to drop or resolve patent litigation so that the cheaper generic is prevented from coming to market.
- The jury said that plaintiffs absorbed nearly $885M in damages.
More on Takeda Pharmaceutical
- Takeda's Rich Pipeline Optionality Is Worth A 'Buy'
- Takeda Pharmaceutical Company Limited (TAK) Q4 2026 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited 2026 Q4 - Results - Earnings Call Presentation
- Takeda to shed 4,500 jobs as part of cost-cutting drive
- Takeda Pharmaceutical Non-GAAP EPS of ¥517.00, revenue of ¥4505.7B; gives FY2026 forecast
推薦文章
一周財經日曆 | 壓軸登場！小米、拼多多等重磅財報來襲；深演智能、雲英谷科技等新股下周上市；港美股下周一休市一日
港股周報 | 利好共振！芯片股集體狂飆，兆易創新周漲超43%；阿里致股東信：將AI+雲打造成新增長動力；聯想飆漲20%刷歷史新高
美股機會日報 | 今晚11點！特朗普將親自「加冕」美聯儲新主席沃什；英偉達Vera Rubin機架售價狂飆！產業鏈所有組件迎漲價熱潮
SpaceX在發現多項問題后推迟「星艦」第12次試飛
華盛早報 | 沃什今晚11點宣誓就職美聯儲主席！雷軍稱未來兩年內存或持續漲價；Q1恆指季檢結果今晚公佈
特朗普再威脅伊朗交出濃縮鈾！稱到手后或銷燬
美股機會日報 | 伊朗稱高濃縮鈾不得運往國外；特朗普再出手！美國政府20億美元佈局量子計算；SpaceX正式遞表衝刺納斯達克
一圖看懂 | 連續兩季盈利！蔚來Q1經營利潤0.66億元，交付量超8萬輛；毛利率創近四年新高
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
